Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Breast Cancer Res. 2004;6(6):R636-9. Epub 2004 Sep 22.

The progesterone receptor Val660-->Leu polymorphism and breast cancer risk.

Author information

  • 1Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. nhidv@channing.harvard.edu

Abstract

BACKGROUND:

Recent evidence suggests a role for progesterone in breast cancer development and tumorigenesis. Progesterone exerts its effect on target cells by interacting with its receptor; thus, genetic variations, which might cause alterations in the biological function in the progesterone receptor (PGR), can potentially contribute to an individual's susceptibility to breast cancer. It has been reported that the PROGINS allele, which is in complete linkage disequilibrium with a missense substitution in exon 4 (G/T, valine-->leucine, at codon 660), is associated with a decreased risk for breast cancer.

METHODS:

Using a nested case-control study design within the Nurses' Health Study cohort, we genotyped 1252 cases and 1660 matched controls with the use of the Taqman assay.

RESULTS:

We did not observe any association of breast cancer risk with carrying the G/T (Val660-->Leu) polymorphism (odds ratio 1.10, 95% confidence interval 0.93-1.30). In addition, we did not observe an interaction between this allele and menopausal status and family history of breast cancer as reported previously.

CONCLUSION:

Overall, our study does not support an association between the Val660-->Leu PROGINS polymorphism and breast cancer risk.

PMID:
15535845
[PubMed - indexed for MEDLINE]
PMCID:
PMC1064075
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Write to the Help Desk